Oral Presentation 20th Lancefield International Symposium on Streptococci and Streptococcal Diseases 2017

Where are we at with treatment and control of group A streptococcal impetigo? (#11)

Asha Bowen 1
  1. Telethon Kids Institute, Wembley, WA, Australia

The global burden of impetigo at any one time is in excess of 160 million children, with impetigo featuring in the top 50 diseases in global burden studies. In tropical contexts, impetigo is predominantly driven by Group A streptococcus (GAS). Recent advances in treatment of impetigo include the use of short course oral cotrimoxazole and treatment of scabies with ivermectin to reduce the community burden of both scabies and impetigo. Translating this evidence into clinical practice through guidelines and clinical trials is ongoing in Australia and internationally.